CClinicalTrials.gg
Status unknownNCT04605354Updated Oct 28, 2020

Epidemiological and Clinical Description of Women Living With HIV in Selected Countries of Latin America

An observational study in HIV-1-infection and Hiv, sponsored by Helios Salud. Status unknown at 1 site in Argentina. Open to female participants. Per ClinicalTrials.gov, last updated 2020-10-28.

Sponsored by Helios Salud · Observational

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Ecologic or community
Time perspective
Retrospective
Enrollment
25,816
Sex
Female
01

Study summary

A cross-sectional study that uses ecological data from (1) PLWHIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV.

Read the detailed description

General Aims Aim 1: Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.

Aim 2: Management of HIV infection during pregnancy in women from selected countries of Latin America.

Countries: Argentina, Bolivia, Chile, Colombia, Costa Rica,Ecuador, Guatemala, Honduras, México, Peru, Dominican, Republic, Uruguay, and Venezuela.

Background \& Relevance of this specific study:

Research Approach:

The Latin American Workshop for HIV Studies (LAW-HIV) includes more than 70 clinical centers belonging to 14 Spanish speaking countries from the region. It gathers aggregate information form more than 116.000 people living with HIV under care, from which 25,802 are women.

These numbers represent roughly a fifth of the total estimated female under care in these countries.

Specific aims from overall aim 1:

The investigators will determine at center, national and regional level:

  • The age distribution of women under care for HIV infection as of December 31st, 2017.
  • The fraction of women under care who are receiving ART as of December 31st, 2017.
  • The age distribution of women admitted to care for years 2013, 2014, 2015, 2016 and 2017.
  • The fraction of admitted women that start ART during the first year after admission, by year of admission.
  • Frequency of selected type of drugs (for backbone and 3rd drug) used for the first cART, by year of admission and age group.
  • The frequency late and very late presenters (CD4) in women admitted according to year of admission and age group.
  • The fraction of women alive, retained to care, retained to ART, and with virologic suppression at one year of follow up, from admissions occurred in 2016.

Specific aims from overall aim 2:

The investigators will determine:

  • The fraction of women with HIV diagnosis occurred as consequence of the pregnancy.
  • Earliest CD4 level and viral load in pregnant women under care by HIV.
  • The fraction of women that suspend ART during pregnancy; frequency of each scheme of ART used previous the conception; and change of scheme (3rd drug and backbone).
  • The fraction of women whose pregnancy ended in term, preterm or as abortion.
  • The fraction of women retained in control post pregnancy.
  • The fraction of women that suspended breastfeeding Data Collection \& Quality:

Study Design:

A cross-sectional study that uses ecological data from (1) People living with HIV under care at 31st December 2017, and (2) from yearly admissions to care occurred during 2013 - 2017, from centers belonging to LAW-HIV. Data will be weighted by the expected population under care in each country considering attributes of the centers (private/public). Weighted outcomes at strata level from each center will be meta-analyzed considering three levels of heterogeneity (stratum, center, and country) and modeled through multilevel regression models to allow adjustment for covariables of the stratum. In the case of admissions to care, a time series analysis will be implemented.

Data collection and quality control:

Data collection will be carried out through a spreadsheet sent to centers that agree to participate. Two different spreadsheets will be sent, one for each general aim of the study (see the annex at the complete project). A quality check will be implemented at three stages: (1) at the moment of receiving each spreadsheet back; (2) previous to analysis, where the consistency of information across strata from different sections will be assessed; and (3) identifying outlier values from outcomes at the centers level, using expert criteria.

Data information included:

  1. Center description (health care staff, ART \& labs (e.g. viral load determinations) availability)
  2. Demographic and clinical features of women under control and admitted (age, CD4, the scheme of ART, retention to care, retention to ART, virologic suppression one year later the admission).
  3. Clinical features of pregnant women under care infected by HIV.

Total duration: 18 months.

02

Conditions studied

  • HIV-1-infection
  • Hiv

Keywords

  • Women
  • Latin America
03

In context

Lead sponsor

Helios Salud is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

For the overall aim 1, the investigators expected to include information about 25,816 women under care, and between 6,000 and 7,500 women admitted during 2013 - 2017 (depending on the sub-analysis), from 14 countries and 79 centers.

For the overall aim 2, the investigators expect to include aggregated information from roughly 400 pregnant females, from at least ten countries. It is worth noticing that the analytic unit corresponds to the information at the stratum level and depending on the disposition of the information in the database, the total numbers of strata will vary between approximately 400 to 8.000.

Eligibility criteria

  • All Latin American HIV care centers from any Spanish speaking country are invited to participate in the LAW-HIV.
  • Only centers that provide a minimum of information (at least sections 1 and 2 from the datasheet for aim 1) will be included in the analysis
05

Study design

Observational model
Ecologic or community
Time perspective
Retrospective
Enrollment
25,816 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Epidemiological and clinical description of women that receive HIV care in selected countries of Latin America.

    1.1. In women admitted to care between years 2013-2017, the trend in the: * distribution of ages; * proportion of late presenters (CD4). * proportion that start ART during the first year after admission; * schemes of ART used for the first ART. 1.2. Proportion of women alive, retained to care, retained to ART, and with virologic suppression at one year of follow up, from admissions occurred in 2016.

    Time frame: 1 year

  2. Management of HIV infection during pregnancy in women from selected countries of Latin America.

    2. In women that finished their pregnancy at any moment during 2019: * Proportion with HIV diagnosis as consequence of the pregnancy. * Earliest CD4 level. * Proportion that suspended ART during pregnancy * Frequency of each scheme of ART used previous the conception * Change of scheme of ART * Proportion whose pregnancy ended in term * Proportion retained in care during the first 6 months after pregnancy * Proportion that suspended breastfeeding during the first 3 months after pregnancy

    Time frame: 1 year

07

Study locations

1 site
  • Helios Salud
    Buenos Aires, C1141, Argentina
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04605354
Lead sponsor
Helios Salud
Collaborators
ViiV Healthcare
Responsible party
Sponsor
First posted
Oct 28, 2020
Start date
Jul 1, 2020
Primary completion
Jan 1, 2022 (estimated)
Completion
Jan 1, 2022 (estimated)
Last update
Oct 28, 2020

Study contacts

Isabel Cassetti, MD
principal investigator · Helios Salud

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion